Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL38 for Intraoperative Imaging of Lung Nodules
NCT02872701Phase 2Completed
- Sponsor
- On Target Laboratories
- Start
- May 2017
- Primary completion
- Oct 2018
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of pafolacianine in lung cancer, sponsored by On Target Laboratories. Primary endpoints: Sensitivity or True Positive Rate (TPR) at 1 day and False Positive Rate at 1 day. Started May 2017; status: completed.
02
Drugs
pafolacianine
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT02872701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872701.